

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box →

+

PTO/SB/08B (6-95)
Approved for use through 07/31/96, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE1449B/PTO
Rev. 10/95U.S. Department of Commerce
Patent and Trademark Office

Complete if Known

LIST OF PRIOR ART CITED BY
APPLICANT

(use as many sheets as necessary)

Application Number	10/502,464
Filing Date	July 26, 2004
First Named Inventor	Carmen V. SCIORTINO, Jr., Ph.D.
Group Art Unit	1645
Examiner Name	GANGLE, Brian J.
Attorney Docket Number	US 1396/04 (VA)

Sheet

6

of

7

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T ²
/BG/		Biotec Laboratories Limited. 2002. Biotec In Development. Web site: http://www.biotec.co.uk/development.html . (April 29, 2002.)	
		BIVDA. 2000. British In Vitro Diagnostics Association. IVD - Healthcare Survey. Web site: http://www.bivda.co.uk/laboratory/index.html. (April 16, 2002.)	
/BG/		Chamberlain, N. 2002. Pseudomonas infections. Kirksville College of Osteopathic Medicine. Web site: http://www.kcom.edu/faculty/chamberlain/Website/tritizid/pseudinf.htm (April 29, 2002.)	
/BG/		Commonwealth Biotechnologies, Inc. 2002. Web site: http://www.cbi-biotech.com . (April 29, 2002.)	
/BG/		De Vos, D., Bouton, C., Sarniguet, A., De Vos, P., Vauterin, M., and P. Cornelis. 1998. Sequence diversity of the oprI gene, coding for major outer membrane lipoprotein I, among rRNA group I Pseudomonads. J. Bacteriol. 180: 6551-6556.	
/BG/		De Vos, D., Lim, A. Jr., De Vos, P., Sarniguet, A., Kersters, K., and P. Cornelis. 1993. Detection of the outer membrane lipoprotein I and its gene in fluorescent and non-fluorescent pseudomonads: implications for taxonomy and diagnosis. J. Gen. Microbiol. 139:2215-2223.	
/BG/		Dini, L.A., Cockinos, C., Frean, J.A., Niszl, I.A., and M.B. Markus. 2000. Unusual case of <i>Acanthamoeba polyphaga</i> and <i>Pseudomonas aeruginosa</i> keratitis in a contact lens wearer from Gauteng, South Africa. J. Clin. Microbiol. 38:826-829.	
/BG/		Emori, T.G. and R.P. Gaynes. 1993. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin. Microbiol. Rev. 10:428-442.	
/BG/		Finke, M., Duchene, M., Eckhardt, A., Domdey, H., and B.U. von Specht. 1990. Protection against experimental <i>Pseudomonas aeruginosa</i> infection by recombinant <i>P. aeruginosa</i> lipoprotein I expressed in <i>Escherichia coli</i> . Infect. Immun. 58:2241-2244.	
		Iglewski, B. 2002. Pseudomonas. UTMB Graduate School of Biomedical Sciences. Web site: http://gsbe.utmb.edu/microbook/ch027.htm. (April 29, 2002.)	

Examiner
Signature

/Brian Gangle/

Date
Considered

04/04/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.